Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy

References

• Eigenbrodt E, Reinacher M, Scheefers Borchel U, Scheefers H, Friis RR. Double role of pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. In: Critical Reviews in Oncogenesis. Perucho M (Ed.). CRC Press, FL, USA, 91–115 (1992).
   Google Scholar
• Staal GEJ, Rijksen G. Pyruvate kinase in selected human tumors. In: Biochemical and Molecular Aspects of Selected Cancers. Pretlow TG, Pretlow TP (Eds). Academic Press, CA, USA, 313–337 (1991).
   Google Scholar
• Mazurek S, Hugo F, Boschek CB, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol.15, 300–308 (2005).
   PubMed Web of Science ®Google Scholar
• Paus E, Myklebust AT. Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer. Tumour Biol.17, 271–280 (1996).
   Google Scholar
• Mazurek S, Eigenbrodt E, Failing K, Steinberg P. Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. J. Cell Physiol.181, 136–146 (1999).
   Google Scholar
• Eigenbrodt E, Glossmann H. Glycolysis – one of the keys to cancer? Trends Pharmacol. Sci1, 240–245 (1980).
   Web of Science ®Google Scholar
• Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J. Bioenerg. Biomembr.29, 315–330 (1997).
   PubMed Web of Science ®Google Scholar
• Eigenbrodt E, Mazurek S, Friis RR. Double role of pyruvate kinase type M2 in the regulation of phosphometabolite pools. In: Cell Growth and Oncogenesis. Bannasch P, Kanduc D, Papa S, Tager JM (Eds). Birkhäuser Verlag, Basel, Germany 15–30 (1998).
   Google Scholar
• Oremek GM, Gerstmeier F, Sauer-Eppel H et al. Pre-analytical problems in the measurement or tumor type pyruvate kinase (Tumor M2-PK). Anticancer Res.23, 1127–1130 (2003).
   Google Scholar
• Oremek GM, Muller R, Sapoutzis N et al. Pyruvate kinase type tumor M2 plasma levels in patients with rheumatic diseases. Anticancer Res.23, 1131–1134 (2003).
   Google Scholar
• Oremek GM, Rutner F, Sapoutzis N et al. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy. Anticancer Res.23, 1155–1158 (2003).
   Google Scholar
• McDowell G, Gupta S, Dellerba M et al. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure. Ann. Clin. Biochem.41, 491–493 (2004).
   PubMed Web of Science ®Google Scholar
• Hardt PD, Ngoumou BK, Rupp J et al. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res.20, 4965–4968 (2000).
   Google Scholar
• Ventrucci M, Cipolla A, Racchine C et al. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig. Dis. Sci.49, 1149–1155 (2004).
   PubMed Web of Science ®Google Scholar
• Oehler R, Weingartmann G, Manhart N et al. Polytrauma induces increased expression of pyruvate kinase in neutrophils. Blood95, 1086–1092 (2000).
   PubMed Web of Science ®Google Scholar
• Oremek GM, Eigenbrodt E, Radle J et al. Value of the serum level of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res.17, 3031–3033 (1997).
   Google Scholar
• Cerwenka H, Aigner R, Bacher H et al. TUM2-PK (pyruvate type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res.19, 849–852 (1999).
   Google Scholar
• Kumar Y, Gurusamy K, Pamecha V, Davidson BR. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas35(2), 114–119 (2007).
   PubMed Web of Science ®Google Scholar
• Schulze G. The tumor marker Tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res.20, 4961–4964 (2000).
   Google Scholar
• Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (Tumor M2-PK), carcinoembryogenic antigen (CEA), carbohydrate antigens CA19-9 and CA72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res.23, 5089–5094 (2003).
   PubMedGoogle Scholar
• Kim CW, Kim JI, Park SH et al. Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer. Korean J. Gastroenterol.42, 387–393 (2003).
   Google Scholar
• Zhang B, Chen JY, Chen DD et al. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J. Gastroenterol.10, 1643–1646 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumor M2-pyruvate kinase: a gastrointestinal cancer marker. Eur. J. Gastroenetrol. Hepatol.19(3), 265–276 (2007).
   PubMed Web of Science ®Google Scholar
• Lamerz R. SCCA (sqamous cell carcinoma antigen). In: Labor und Diagnose. Thomas L (Ed.). TH-Books Verlagsgesellschaft mbH, Frankfurt, Germany 1351–1355 (2005).
   Google Scholar
• Lamerz R. CA 19-9, GICA (gastrointestinal cancer antigen). In: Labor und Diagnose. Thomas L (Ed.). TH-Books Verlagsgesellschaft mbH, Frankfurt, Germany 1302–1305 (2005).
   Google Scholar
• Lamerz R. CA 72-4 (TAG-72). In: Labor und Diagnose. Thomas L (Ed.). TH-Books Verlagsgesellschaft mbH, Frankfurt, Germany 1310–1313 (2005).
   Google Scholar
• Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas34(3), 318–324 (2007).
   PubMedGoogle Scholar
• Pinedo R, Faroq R, Davidson BR. Tumour M2-PK: comparative study of the value of tumour markers in the diagnosis of colorectal liver metastasis. Gut54(2), A29 (2005).
   Google Scholar
• Schneider J, Bitterlich N, Schulze G. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic based tumor marker profiles including the Tumor M2-PK. Anticancer Res.25, 1507–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Guittet L, Bouvier V, Mariotte N et al. Comparison of a Guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut56, 210–214 (2007).
   PubMed Web of Science ®Google Scholar
• Hardt PD, Toepler M, Ngoumou B et al. Measurement of fecal pyruvate kinase type M2 (Tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res.23, 851–854 (2003).
   Google Scholar
• Hardt PD, Mazurek S, Toepler M et al. Faecal tumor M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br. J. Cancer91, 980–984 (2004).
   PubMed Web of Science ®Google Scholar
• Naumann M, Schaum B, Oremek GM et al. Pyruvatkinase typ M2 (M2-PK) im stuhl – ein valider screeningparameter für kolorektale neoplasien? Dtsch. Med. Wochenschr.129, 1806–1807 (2004).
   Google Scholar
• Vogel T, Driemel C, Hauser A et al. Vergleich verschiedener stuhltests zur detektion von neoplasien des kolon. Dtsch. Med. Wochenschr.130, 872–877 (2005).
   Google Scholar
• Koss K, Maxton D, Jankowski J. The potential use of fecal dimeric M2 pyruvate kinase (tumour M2PK) in screening for colorectal cancer. Gut54(Suppl. 2), A20 (2005).
   Google Scholar
• Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal Tumor M2-PK. World J. Gastroenterol.12, 7007–7011 (2006).
   PubMedGoogle Scholar
• Shastri YM, Naumann M, Oremek GM et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int. J. Cancer119, 2651–2656 (2006).
   Google Scholar
• Mulder SA, van Leerdam ME, van Vuuren AJ et al. Pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur. J. Gastroenterol. Hepatol.19(10), 878–882 (2007).
   Google Scholar
• Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br. J. Cancer96(9), 1329–1334 (2007).
   PubMedGoogle Scholar
• Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis.10(3), 244–248 (2008).
   Google Scholar
• Alquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. N. Engl. J. Med.312, 1422–1428 (1985).
   Google Scholar
• Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst. Rev.2, CD001216 (1998).
   Google Scholar
• Macrae FA, St John DJ. Relationship between patterns of bleeding and Haemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology82, 891–898 (1982).
   PubMed Web of Science ®Google Scholar
• Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N. Engl. J. Med.328, 1365–1371 (1993).
   PubMed Web of Science ®Google Scholar
• Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J. Natl Cancer Inst.91, 434–437 (1999).
   PubMed Web of Science ®Google Scholar
• Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet348, 1467–1471 (1996).
   PubMed Web of Science ®Google Scholar
• Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut50, 29–32 (2002).
   PubMed Web of Science ®Google Scholar
• Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal occult- blood screening for colorectal cancer. Lancet348, 1472–1477 (1996).
   PubMed Web of Science ®Google Scholar
• Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N. Engl. J. Med.343, 1603–1607 (2000).
   PubMed Web of Science ®Google Scholar
• Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis? Nat. Rev. Cancer5(3), 199–209 (2005).
   PubMed Web of Science ®Google Scholar